Justin C Brown1, Andrea B Troxel2, Bonnie Ky3, Nevena Damjanov4, Babette S Zemel5, Michael R Rickels6, Andrew D Rhim7, Anil K Rustgi8, Kerry S Courneya9, Kathryn H Schmitz10. 1. Division of Population Science & Gastrointestinal Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Electronic address: justinc_brown@dfci.harvard.edu. 2. Department of Population Health, NYU School of Medicine, New York, NY. 3. Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA. 4. Division of Medical Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA. 5. Division of Gastroenterology, Hepatology and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, PA. 6. Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Pennsylvania, Philadelphia, PA. 7. Department of Gastroenterology, Hepatology and Nutrition, M.D. Anderson Cancer Center, Houston, TX. 8. Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA. 9. Department of Physical Activity and Recreation, University of Alberta, Edmonton, Alberta, Canada. 10. Department of Public Health Science, College of Medicine, Penn State College of Medicine, Hershey, PA.
Abstract
BACKGROUND: Observational studies suggest that higher volumes of physical activity are associated with a lower risk of disease recurrence among survivors of colon cancer. However, the feasibility and safety of prescribing higher volumes of physical activity to survivors of colon cancer are unknown. Furthermore, the pathways through which exercise may reduce disease recurrence are unknown. PATIENTS AND METHODS: Survivors of stageI to III colon cancer were randomized to usual-care control, 150 minutes per week of aerobic exercise (low-dose), or 300 minutes per week of aerobic exercise (high-dose). Changes in soluble intercellular adhesion molecule-1 and vascular adhesionmolecule-1 prognostic biomarkers were examined. RESULTS:From January 2015 to February 2016, 39 patients were enrolled (n = 13 usual-care control; n = 14 low-dose; n = 12 high-dose), and 38 participants completed the study (97% follow-up). Over 6 months, the low-dose group completed 142 minutes per week (92.8% adherence), and the high-dose group completed 247 minutes per week (89.0% adherence) of exercise. Compared with the control group, changes in soluble intercellular adhesion molecule-1 were -134.9 ng/mL (95% confidence interval, -238.1 to -31.6 ng/mL) in the low-dose group and -114.8 ng/mL (95% confidence interval, -222.5 to -7.1 ng/mL) in the high-dose group (linear Ptrend = .023; nonlinear Ptrend = .044). No changes were observed for soluable vascular adhesion molecule-1 (linear Ptrend = .791; nonlinear Ptrend = .604). Non-serious adverse events occurred at similar rates among randomized groups. No serious adverse events occurred. CONCLUSION: Higher volumes of moderate-intensity aerobic exercise, up to 300 minutes per week, are feasible, safe, and elicit favorable changes in prognostic biomarkers among patients recently treated for stageI to III colon cancer. These data can be used to guide clinical recommendations for patients, and inform future trials.
RCT Entities:
BACKGROUND: Observational studies suggest that higher volumes of physical activity are associated with a lower risk of disease recurrence among survivors of colon cancer. However, the feasibility and safety of prescribing higher volumes of physical activity to survivors of colon cancer are unknown. Furthermore, the pathways through which exercise may reduce disease recurrence are unknown. PATIENTS AND METHODS: Survivors of stage I to III colon cancer were randomized to usual-care control, 150 minutes per week of aerobic exercise (low-dose), or 300 minutes per week of aerobic exercise (high-dose). Changes in soluble intercellular adhesion molecule-1 and vascular adhesion molecule-1 prognostic biomarkers were examined. RESULTS: From January 2015 to February 2016, 39 patients were enrolled (n = 13 usual-care control; n = 14 low-dose; n = 12 high-dose), and 38 participants completed the study (97% follow-up). Over 6 months, the low-dose group completed 142 minutes per week (92.8% adherence), and the high-dose group completed 247 minutes per week (89.0% adherence) of exercise. Compared with the control group, changes in soluble intercellular adhesion molecule-1 were -134.9 ng/mL (95% confidence interval, -238.1 to -31.6 ng/mL) in the low-dose group and -114.8 ng/mL (95% confidence interval, -222.5 to -7.1 ng/mL) in the high-dose group (linear Ptrend = .023; nonlinear Ptrend = .044). No changes were observed for soluable vascular adhesion molecule-1 (linear Ptrend = .791; nonlinear Ptrend = .604). Non-serious adverse events occurred at similar rates among randomized groups. No serious adverse events occurred. CONCLUSION: Higher volumes of moderate-intensity aerobic exercise, up to 300 minutes per week, are feasible, safe, and elicit favorable changes in prognostic biomarkers among patients recently treated for stage I to III colon cancer. These data can be used to guide clinical recommendations for patients, and inform future trials.
Authors: Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler Journal: CA Cancer J Clin Date: 2012-04-26 Impact factor: 508.702
Authors: Justin C Brown; Andrea B Troxel; Bonnie Ky; Nevena Damjanov; Babette S Zemel; Michael R Rickels; Andrew D Rhim; Anil K Rustgi; Kerry S Courneya; Kathryn H Schmitz Journal: Contemp Clin Trials Date: 2016-03-10 Impact factor: 2.226
Authors: Heidi Nelson; Daniel J Sargent; H Sam Wieand; James Fleshman; Mehran Anvari; Steven J Stryker; Robert W Beart; Michael Hellinger; Richard Flanagan; Walter Peters; David Ota Journal: N Engl J Med Date: 2004-05-13 Impact factor: 91.245
Authors: Richard P Troiano; David Berrigan; Kevin W Dodd; Louise C Mâsse; Timothy Tilert; Margaret McDowell Journal: Med Sci Sports Exerc Date: 2008-01 Impact factor: 5.411
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Justin C Brown; Nevena Damjanov; Kerry S Courneya; Andrea B Troxel; Babette S Zemel; Michael R Rickels; Bonnie Ky; Andrew D Rhim; Anil K Rustgi; Kathryn H Schmitz Journal: Psychooncology Date: 2018-02-20 Impact factor: 3.894
Authors: Pedro Lopez; Daniel A Galvão; Dennis R Taaffe; Robert U Newton; Giovani Souza; Gabriel S Trajano; Ronei S Pinto Journal: Breast Cancer Date: 2020-08-19 Impact factor: 4.239
Authors: Justin C Brown; Michael R Rickels; Andrea B Troxel; Babette S Zemel; Nevena Damjanov; Bonnie Ky; Andrew D Rhim; Anil K Rustgi; Kerry S Courneya; Kathryn H Schmitz Journal: Endocr Relat Cancer Date: 2017-10-10 Impact factor: 5.678
Authors: Justin C Brown; Babette S Zemel; Andrea B Troxel; Michael R Rickels; Nevena Damjanov; Bonnie Ky; Andrew D Rhim; Anil K Rustgi; Kerry S Courneya; Kathryn H Schmitz Journal: Br J Cancer Date: 2017-09-21 Impact factor: 7.640
Authors: Justin C Brown; Andrew D Rhim; Sara L Manning; Luke Brennan; Alexandra I Mansour; Anil K Rustgi; Nevena Damjanov; Andrea B Troxel; Michael R Rickels; Bonnie Ky; Babette S Zemel; Kerry S Courneya; Kathryn H Schmitz Journal: PLoS One Date: 2018-10-17 Impact factor: 3.240